Comment
. 2012 Sep;64(9):3057-8; author reply 3058.
doi: 10.1002/art.34590.
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al
- PMID: 22729507
- DOI: 10.1002/art.34590
Item in Clipboard
Comment
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al
Arthritis Rheum.
2012 Sep.
No abstract available
Comment on
-
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum. 2012 Feb;64(2):542-8. doi: 10.1002/art.33361. Arthritis Rheum. 2012. PMID: 21953279
Similar articles
-
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum. 2012 Feb;64(2):542-8. doi: 10.1002/art.33361. Arthritis Rheum. 2012. PMID: 21953279
-
Antineutrophil cytoplasmic autoantibodies: an unbiased and efficient tool to classify renal vasculitis? Comment on the article by Lionaki et al.Arthritis Rheum. 2013 May;65(5):1405-6. doi: 10.1002/art.37892. Arthritis Rheum. 2013. PMID: 23400524 No abstract available.
-
Recognition of Rare, Atypical Manifestations Is Important for Diagnosis and Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Comment on the Article by Delaval et al.Arthritis Rheumatol. 2021 Apr;73(4):719. doi: 10.1002/art.41590. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33191641 No abstract available.
-
Overlap syndrome: juvenile dermatomyositis and perinuclear antineutrophil cytoplasmic autoantibody vasculitis, a case report and review of literature.Int J Rheum Dis. 2017 Dec;20(12):2219-2224. doi: 10.1111/1756-185X.13142. Epub 2017 Jul 27. Int J Rheum Dis. 2017. PMID: 28752636 Review. No abstract available.
-
Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis.Curr Opin Rheumatol. 2015 Jan;27(1):38-44. doi: 10.1097/BOR.0000000000000135. Curr Opin Rheumatol. 2015. PMID: 25405826 Review.
Cited by
-
Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.Front Immunol. 2022 Mar 24;13:777134. doi: 10.3389/fimmu.2022.777134. eCollection 2022. Front Immunol. 2022. PMID: 35401565 Free PMC article.
-
The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.Oncotarget. 2017 May 23;8(32):52072-52077. doi: 10.18632/oncotarget.18120. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881714 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
